NCT04751227

Modafinil for Wakefulness in the Critical Care Units

Modafinil for Wakefulness in the Critical Care Units and COVID-19 Patients at a Tertiary Care Saudi Hospital

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 8 (actual)
• Sponsor: King Faisal Specialist Hospital & Research Center · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: —

Summary

It has been well documented that patients in the intensive care unit (ICU) are susceptible to developing neurocognitive and musculoskeletal complications because of various factors, including the nature of the critical illness, medications, over-sedation, and pain. Neuro-stimulants are used to speed up physical and mental processes through the increase in neurotransmitter, which translates into increase in arousal, wakefulness, attention, memory, mental and motor processing speed. The investigators reviewed the literature and described the clinical characteristics for a case series of adult patients admitted to COVID and non-COVID ICU between January 2017 and June 2020, who received modafinil to promote wakefulness and improve cognition at the King Faisal Specialist Hospital and Research Centre (KFSH\&RC) in Riyadh, Saudi Arabia. The secondary goals to describe the change of Glasgow Coma Scale (GCS) before and after the start of modafinil therapy, ICU and hospital length of stay, discharge disposition, adverse drug effects, and mortality rate.

Conditions

• Critical Illness
• COVID-19
• Cognitive Dysfunction

Interventions

Type	Name	Description
DRUG	Modafinil	100-200 mg oral daily for for Wakefulness in the Critical Care Units

Timeline

• Start date: 2020-11-22
• Primary completion: 2021-01-30
• Completion: 2021-01-30
• First posted: 2021-02-12
• Last updated: 2021-02-12

Locations

1 site across 1 country: Saudi Arabia

Regulatory

• FDA-regulated drug study